Dermata Therapeutics (DRMA) Other financing activities (2023 - 2025)

Dermata Therapeutics (DRMA) posted quarterly Other financing activities of $977.0 for Q1 2025, up 3.83% quarter-over-quarter from $941.0 in Q4 2024.

Dermata Therapeutics (DRMA) Other financing activities (2023 - 2025) Analysis & Trends

Dermata Therapeutics' Other financing activities history runs 3 years deep, the most recent figure standing at $977.0 for Q1 2025.

In Q1 2025, Other financing activities changed N/A year-over-year to $977.0; the TTM figure through Dec 2025 stood at $977.0 (down 11.9% YoY), while the FY2025 annual figure was $977.0, down 11.9% from the prior year.
Other financing activities for Q1 2025 stood at $977.0, up from $941.0 in the prior quarter.
The five-year high for Other financing activities was $977.0 in Q1 2025, with the low at $34.0 in Q2 2023.
The 3-year median for Other financing activities is $168.0 (2024), against an average of $454.6.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn
10	Dermata Therapeutics	5.33 Mn	5.33 Mn	-

Download Data